An intranasal stringent response vaccine targeting dendritic cells as a novel adjunctive therapy against tuberculosis

An intranasal stringent response vaccine targeting dendritic cells as a novel adjunctive therapy against tuberculosis

Lengthy tuberculosis (TB) treatment is required to overcome the ability of a subpopulation of persistent Mycobacterium tuberculosis (Mtb) to remain in a non-replicating, antibiotic-tolerant state characterized by metabolic remodeling, including induction of the RelMtb-mediated stringent response. We...

Full description

Bibliographic Details
Main Authors: Styliani Karanika, James T. Gordy, Pranita Neupane, Theodoros Karantanos, Jennie Ruelas Castillo, Darla Quijada, Kaitlyn Comstock, Avinaash K. Sandhu, Aakanksha R. Kapoor, Yinan Hui, Samuel K. Ayeh, Rokeya Tasneen, Stefanie Krug, Carina Danchik, Tianyin Wang, Courtney Schill, Richard B. Markham, Petros C. Karakousis
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Immunology
Subjects:
Mycobacterium tuberculosis
tuberculosis DNA vaccines
persistence
stringent response
immunotherapy
intranasal route
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.972266/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.972266/full

Similar Items